Our Work

Latham & Watkins Advises Sanofi on Co-Exclusive Licensing Agreement With Novavax

May 22, 2024
Multidisciplinary team advised the healthcare company on deal to co-commercialize COVID-19 vaccine and develop novel flu-COVID-19 combination vaccines.

As part of Sanofi’s commitment to developing a diverse portfolio of best-in-class vaccines, the company has announced it entered into a co-exclusive licensing agreement with, and minority equity investment (<5%) in, Novavax, a biotechnology company headquartered in Maryland, US.

Latham & Watkins LLP advised Sanofi in the agreement, with a healthcare and life sciences team led by New York partner Aaron Gardner with associate Robert Yeh. Advice on the minority equity investment was provided by New York partner Nathan Ajiashvili, with associates Kaj Nielson and Sheen Moaleman. Century City partner Andrew Clark advised on corporate and due diligence matters, with counsel Darryl Steensma and associates Brianna Dollinger, Michael Sweeney, Drew O’Sullivan, Mark Goshgarian, Gary Mo, Diana Chung, Enrique Covarrubias, Aldrich Huang, and Patrick Chew.